Trans American Aquaculture, Inc. GRPS OTC · Healthcare · United States
$0.00 +0.00% +$0.00
Summary
29 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 36,111 USD is left as free cash.
- The price moves less than the market (beta 0.18).
What to watch
- Revenue fell by 57% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue fell by 57% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $2.13M.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.